INFORMATION DISCLOSURE	:
STATEMENT BY APPLICANT	
(Not for submission under 37 CFR 1.99)	

Application Number		10687035
Filing Date		2003-10-15
First Named Inventor	Earl F	. Albone
Art Unit		1642
Examiner Name	Laura	B. Goddard, Ph.D.
Attorney Docket Number		210121.727

U.S.PATENTS							Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines where Relevant Passages or Relev Figures Appear		
	1									
If you wish to add additional U.S. Patent citation information please click the Add button.							Add			
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹		Publication Name of Patentee or Applicant of cited Document			Releva	,Columns,Lines whe ant Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ade	d button	Add	
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² j Code ⁴		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Line where Relevant Passages or Releva Figures Appear	T5	
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10687035			
Filing Date		2003-10-15			
First Named Inventor	Earl F	Earl F. Albone			
Art Unit		1642			
Examiner Name	Laura B. Goddard, Ph.D.				
Attornov Dooket Number		240424 727			

/LBG/	1		et al., "Immunohistochemical Characterization of 22 Monoclonal Antibodies against the CA 125 Antigen: 2nd ort from the ISOBM TD-1 Workshop," Tumor Biology 17:325-331, 1996.							
/LBG/	2		ingleton et al., "Characterization of Antibodies to CA 125 that Bind Preferentially to the Cell-Associated Form of the ntigen," Tumor Biology 27:122-132, 2006.							
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examiner Signature /Laura B Goddard/		ture	/Laura B Goddard/	Date Considered	3/27/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a										

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04.
Enter office that issued the document, by the two-letter code (WIPO)

The code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
Enter office that issued the document, by the two-letter code (WIPO)

The code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
Enter office that issued the document, by the two-letter code (WIPO)

The code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
Enter office that issued the document, by the two-letter code (WIPO)

The code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
Enter office that issued the document, by the two-letter code (WIPO)

The code of the code of

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www_USPTO_GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST3.) § For Japanese patent document, bic incidation of the typeror must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.